Auteurs
Corpus
Accueil
Racine
Corpus
Exploration
Accueil
Racine
Accueil
Racine

Serveur d'exploration sur la maladie de Parkinson - Corpus (Accueil)

Index « Auteurs » - entrée « David Oakes »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
David Nicholl < David Oakes < David Otaegui  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 11.
Ident.Authors (with country if any)Title
000250 (2002) Ira Shoulson ; David Oakes ; Stanley Fahn ; Anthony Lang ; J. William Langston ; Peter Lewitt ; C. Warren Olanow ; John B. Penney ; Caroline Tanner ; Karl Kieburtz ; Alice RudolphImpact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
000265 (2009) Connie Marras ; Anthony E. Lang ; Shirley W. Eberly ; David Oakes ; Stanley Fahn ; Steven R. Schwid ; Christopher Hyson ; Ira ShoulsonA comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts
000306 (2010) Steven R. Schwid ; Janice Bausch ; David Oakes ; Lynn Schuchter ; Caroline Tanner ; Misser Forrest ; Anthony E. Lang ; Ira ShoulsonCancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
000358 (2006) Kevin M. Biglan ; Steven Schwid ; Shirley Eberly ; Karen Blindauer ; Stanley Fahn ; Tamar Goren ; Karl Kieburtz ; David Oakes ; Sandra Plumb ; Andrew Siderowf ; Matthew Stern ; Ira ShoulsonRasagiline improves quality of life in patients with early Parkinson's disease
000392 (2011) Michael A. Schwarzschild ; Kenneth Marek ; Shirley Eberly ; David Oakes ; Ira Shoulson ; Danna Jennings ; John Seibyl ; Alberto AscherioSerum urate and probability of dopaminergic deficit in early “Parkinson's disease”
000535 (1997) LeWitt ; David Oakes ; Lu CuiThe need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α‐tocopherol
000628 (2009) Bernard Ravina ; Caroline Tanner ; Diane Dieuliis ; Shirley Eberly ; Emily Flagg ; Wendy R. Galpern ; Stanley Fahn ; Christopher G. Goetz ; Stephen Grate ; Roger Kurlan ; Anthony E. Lang ; Kenneth Marek ; Karl Kieburtz ; David Oakes ; Robin Elliott ; Ira ShoulsonA longitudinal program for biomarker development in Parkinson's disease: A feasibility study
000A03 (2003) Carson R. Reider ; Cheryl A. Halter ; Peter F. Castelluccio ; David Oakes ; William C. Nichols ; Tatiana ForoudReliability of reported age at onset for Parkinson's disease
001794 (2009) Robert A. Hauser ; Peggy Auinger ; David OakesLevodopa response in early Parkinson's disease
001A87 (2001) Stewart A. Factor ; Joseph H. Friedman ; Margaret C. Lannon ; David Oakes ; Keith BourgeoisClozapine for the treatment of drug‐induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial
001D31 (2006) Samuel M. Goldman ; Caroline M. Tanner ; David Oakes ; Grace S. Bhudhikanok ; Anjali Gupta ; J. William LangstonHead injury and Parkinson's disease risk in twins

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/Author.i -k "David Oakes" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/Author.i  \
                -Sk "David Oakes" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonV1
   |flux=    Main
   |étape=   Corpus
   |type=    indexItem
   |index=    Author.i
   |clé=    David Oakes
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024